m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00031)

Regulator Name	Eukaryotic initiation factor 3 (EIF3A)
Synonyms	EIF3A; EIF3S10; KIAA0139; eIF3a; Eukaryotic translation initiation factor 3 subunit 10; eIF-3-theta; eIF3 p167; eIF3 p180; eIF3 p185; Eukaryotic translation initiation factor 3 subunit A Click to Show/Hide
Gene Name	EIF3A
Regulator Type	WRITER ERASER READER
Regulator Link	Click to View Full Information of This Regulator

Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)

Transforming growth factor beta 1 (TGFB1)

Pirfenidone [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Pirfenidone. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of Pirfenidone through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [2]

LY2157299 [Phase 2/3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [3]

TG-C [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for TG-C. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of TG-C through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [4]

Disitertide [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Disitertide. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of Disitertide through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [5]

ABBV-151 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ABBV-151. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of ABBV-151 through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [6]

SRK-181 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for SRK-181. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of SRK-181 through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [7]

ART-144 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ART-144. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of ART-144 through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [8]

Mannose phosphate [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Mannose phosphate. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of Mannose phosphate through regulating the expression of Transforming growth factor beta 1 (TGFB1).	[1], [9]

References

Ref 1	Knockdown of elF3a inhibits TGF?Beta1?induced extracellular matrix protein expression in keloid fibroblasts. Mol Med Rep. 2018 Mar;17(3):4057-4061. doi: 10.3892/mmr.2017.8365. Epub 2017 Dec 29.
Ref 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3	Clinical pipeline report, company report or official report of Tissue Gene, Inc.
Ref 4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6	Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
Ref 7	Clinical pipeline report, company report or official report of AbbVie.
Ref 8	The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-Beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101. doi: 10.1016/j.imlet.2015.04.003. Epub 2015 Apr 27.
Ref 9	Clinical pipeline report, company report or official report of Scholar Rock.